Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

Switching from liquid to foam minoxidil led to hair loss for OP, possibly due to a second shedding cycle. OP experienced allergic reactions to propylene glycol in the liquid form, causing dandruff and itchiness, which improved after switching to foam.

A user shared their 9-month progress using RU58841 at 2% daily for hair regrowth, initially starting at 5% but reducing the dose due to early signs of gynecomastia, which has since mostly resolved. They achieved their goal of regrowing hair at the temples and hairline.

Hair fibers impressively cover bald spots, boosting confidence. User started big 3 treatment (0.5mg fin, 1 time minoxidil 5% topical, ketoconazole 2%) for regrowth.

Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.

A 28-year-old man shared his experience with a 2990 graft FUE hair transplant at HDC Clinic in Cyprus, praising the professionalism and care received. He has been using topical Minoxidil, Biotin, Dermarolling, and recently started Finasteride and oral Minoxidil.

KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.

Oral copper supplementation significantly improved hair regrowth for someone who experienced severe hair loss after stopping minoxidil, suggesting copper deficiency might hinder minoxidil's effectiveness. The user now only takes copper and occasionally uses microneedling, recommending others to try copper if minoxidil alone isn't effective.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Bayer dismissed HMI-115 due to focus shift away from women's health.

The user has been using finasteride for years with little regrowth and recently started using Cécred edge drops, which have significantly improved their scalp condition. Another user mentioned combining Cécred with derma stamping for better results.

The conversation discusses hair cloning progress and mentions treatments like Minoxidil, finasteride, and RU58841. Users also talk about hair transplants and their effectiveness.

KY19382, a promising compound for hair loss, is not widely discussed or used. One user is currently testing it and plans to share results in a few weeks.

A user who has been using Pyrilutamide for 19 days, experiencing some hair thickening in the right temple and crown area but also having ball ache after microneedling; other users offer advice, caution and skepticism as to whether results can be seen in such a short time.

A sugar gel is claimed to spark hair regrowth, but users express skepticism, noting that minoxidil and finasteride remain the most effective treatments. Many users joke about frequent "breakthroughs" that work on rats but not humans, and some mention the potential of PP405 as a future treatment.

Pyrilutamide, a potential hair loss treatment that has recently been released for sale, and is thought to have similar efficacy to Dutasteride without side effects. It was discussed in terms of its effectiveness compared to Finasteride, its use by females, and whether it can be safely mixed with RU58841.

The conversation is about using GHK-Cu, a copper peptide, for hair loss treatment. Users discuss their experiences, dosages, and additional benefits like improved skin and energy.

The conversation is about the progress of verteporfin in hair loss trials, with users expressing curiosity about its effectiveness and updates. Specific treatments mentioned include FUE (Follicular Unit Extraction) combined with verteporfin, with one reported case of donor area regrowth after a year, and three patients being monitored post-treatment by Dr. Bloxham with monthly updates on YouTube.

Deoxyribose sugar gel is discussed as a potential hair loss treatment, but it lacks human trials and credible evidence. Users express skepticism and humor about its effectiveness compared to established treatments like minoxidil and finasteride.

A recent publication suggests that the flavonoids eriocitrin and silymarin may be more effective than finasteride in binding to the enzyme responsible for hair loss. People in the conversation are skeptical about the effectiveness and safety of these flavonoids until tested on humans, and some discuss their personal experiences with other treatments.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

Amplifica has not provided updates on SCUBE3 and AMP-303, raising concerns about their trial outcomes. Users also mention other treatments like Minoxidil, finasteride, RU58841, PP405, and ET-03.

The user started using minoxidil in September 2024 and finasteride in February 2025, along with dermal rolling, rosemary and clove water, and copper peptide serum for hair growth. They experienced positive hair growth results but had issues with a poorly done scalp micropigmentation (SMP) tattoo, which they are in the process of removing with laser treatments.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

The user is treating hair loss with 1mg finasteride every other day, daily topical minoxidil, and weekly derma rolling, and is considering using hair fibers for special occasions. There is a discussion about the initial shedding phase of minoxidil treatment and the importance of consistent photo conditions to track progress.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

Pyrilutamide/KX-826 is being considered as a potential treatment for female androgenetic alopecia (AGA), but its high cost and limited data on effectiveness are concerns. Kintor markets it for both men and women.

The conversation discusses Dr. Blake Bloxham's experiment with Verteporfin for hair loss, with one person suggesting more doctors should try it as it seems beneficial. Another comment notes that results at 4-5 months were not very impressive.

The conversation discusses creating a topical catalase solution with phosphate buffered saline, glycerin, and polysorbate 20 for hair loss treatment. The user seeks advice on preparing this solution.

User reported initial hair regrowth with 0.25 mg finasteride taken four times a week, experiencing a second shedding phase, and no side effects. They also mentioned using RU58841 without success and plan to stop after a year.

PP405 is a promising new treatment for hair loss. It performs three actions in one, potentially offering a cure.